Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1638 1674 1682
This examiner grants 27% of resolved cases
SHIN, DANA H is an examiner in Tech Center 1600 and Art Unit 1635. The data shows 1168 resolved cases for this examiner. The allowance rate is 27.0 percent, which indicates the proportion of grants among resolved applications. Practitioners can use this 27.0 percent figure to evaluate the probability of a successful outcome. The count of 1168 resolved cases provides a basis for understanding the examiner's historical trends in this art unit.
The interview lift is 27.0 percent. This metric represents the difference in the allowance rate when an interview is conducted compared to the overall rate of 27.0 percent. An interview lift of 27.0 percent suggests that direct communication with the examiner is associated with a significant increase in the probability of receiving a grant. Practitioners should prioritize scheduling interviews to address specific rejections or to clarify technical aspects of the claims. This 27.0 percent lift is a key factor in developing a prosecution strategy.
The median days to allowance is 1217. This number represents the middle value of the time taken from the start of prosecution to the issuance of a patent. A median of 1217 days provides a timeline for applicants to manage their expectations regarding the duration of the process. The combination of the 27.0 percent allowance rate and the 1217-day pendency characterizes the current prosecution environment. These metrics help in planning the resources and time required for applications assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19552507 | ANTISENSE OLIGONUCLEOTIDE OF RasGRP4 | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 18271926 | COMBINATION THERAPEUTICS FOR TREATMENT OF PROLIFERATIVE DISORDERS | Non-Final OA | GEORGIA TECH RESEARCH CORPORATION |
| 18554771 | GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | Non-Final OA | The Regents of the University of California |
| 18271656 | PRIME EDITOR VARIANTS, CONSTRUCTS, AND METHODS FOR ENHANCING PRIME EDITING EFFICIENCY AND PRECISION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18503495 | THERAPEUTIC SPLICE-SWITCHING OLIGONUCLEOTIDES FOR CANCER | Non-Final OA | WASHINGTON UNIVERSITY |
| 18063824 | CELLULAR UPTAKE OF FUNCTIONALIZED DNA NANOSTRUCTURES | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18225400 | SPHERICAL NUCLEIC ACIDS WITH DENDRITIC LIGANDS | Final Rejection | NORTHWESTERN UNIVERSITY |
| 17076607 | SPHERICAL NUCLEIC ACIDS WITH DENDRITIC LIGANDS | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18024182 | COMPOSITIONS AND METHODS FOR TREATING THERAPY RESISTANT CANCER | Non-Final OA | The General Hospital Corporation |
| 16955508 | Bivalent Nucleic Acid Ligands and Uses Therefor | Final Rejection | Carnegie Mellon University |
| 18309443 | MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 17984846 | TRANS-SPLICING RNA (tsRNA) | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 17784045 | INDUCTION OF PROLIFEROUS PANCREATIC ISLET PRECURSOR CELL-LIKE CELLS BY TRANSIENT EXPRESSION OF MYCL AND INDUCTION OF DIFFERENTIATION INTO INSULIN-POSITIVE CELLS | Final Rejection | THE UNIVERSITY OF TOKYO |
| 18567167 | NANOPARTICLE COMPRISING PEPTIDE-LIPID CONJUGATE FOR DELIVERING OLIGONUCLEOTIDE INTO TARGET CELL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17716848 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | Final Rejection | The Scripps Research Institute |
| 18039630 | ADENINE BASE EDITOR HAVING INCREASED THYMINE-CYTOSINE SEQUENCE-SPECIFIC CYTOSINE EDITING ACTIVITY, AND USE THEREOF | Final Rejection | Korea University Research and Business Foundation |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18065570 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 17837352 | RNA GUIDED ERADICATION OF VARICELLA ZOSTER VIRUS | Non-Final OA | Temple University - of The Commonwealth System of higher Education |
| 18710129 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN BACILLUS CELLS | Non-Final OA | DANISCO US INC. |
| 18155655 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Genzyme Corporation |
| 16781732 | COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY | Final Rejection | KSQ Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy